Altimmune Faces Investor Lawsuit Amid Mixed Clinical Trial Results

Biopharmaceutical company Altimmune finds itself navigating turbulent waters as a shareholder class action lawsuit compounds challenges stemming from disappointing clinical trial data. The legal action alleges the company misrepresented interim results from its pivotal IMPACT Phase 2b study of liver treatment pemvidutide, sending shares into a tailspin that erased more than half their value in June.

Legal Woes Compound Clinical Setbacks

Investors filed suit claiming Altimmune overstated positive aspects of its metabolic dysfunction-associated steatohepatitis (MASH) trial while downplaying an unexpectedly strong placebo effect that undermined statistical significance for the primary endpoint of fibrosis reduction. The allegations center on whether management provided misleading statements about the drug candidate’s progress.

Market reaction was swift and severe – shares plummeted 53% in a single trading session, tumbling from $7.71 to $3.61 following the data release. Financial analysts suggest the reputational damage from the lawsuit may prove more damaging long-term than the clinical results themselves, raising questions about the company’s ability to restore investor confidence.

Silver Linings in Financial and Clinical Updates

Amid the controversy, Altimmune’s August 12 quarterly report revealed several positive developments:

Should investors sell immediately? Or is it worth buying Altimmune?

• Reduced net losses of $22.15 million (10.1% improvement)
• Narrower-than-expected per-share loss of $0.27 versus $0.31 projections
• Strengthened liquidity position with $183.1 million cash (39% increase)

The company emphasized encouraging 24-week data from the IMPACT trial showing:

• MASH remission in up to 59.1% of participants
• Fibrosis improvement in 34.5% of patients
• Average weight reduction reaching 6.2%
• Promising cT1 imaging biomarkers

Regulatory Milestones Loom

All eyes now turn to two critical fourth-quarter 2025 events that could determine Altimmune’s future:

• Full 48-week IMPACT study results
• FDA end-of-Phase 2 meeting

Concurrently, the company has initiated two new Phase 2 trials exploring pemvidutide’s potential in alcohol-related disorders (AUD and ALD). Analyst opinions remain divided, with some maintaining buy recommendations while others adopt a wait-and-see approach pending legal resolution and regulatory developments.

For investors, Altimmune presents a high-risk proposition. While the therapeutic data shows clinical promise, the shadow of litigation hangs over every positive development. The coming months will reveal whether management can steer the company through these dual challenges of scientific and legal scrutiny.